1. Demystifying Idiopathic Pulmonary Fibrosis

2. Overview

3. Prevalence of IPF Age and Gender

4. IPF in Medicare Beneficiaries

5. IPF in Medicare Beneficiaries

6. Defining IPF

7. Types of UIP Patterns

8. HRCT Criteria for UIP Pattern

9. HRCT Images of UIP Patterns Fibrosis

10. HRCT Criteria for Possible UIP

11. HRCT Possible UIP Pattern

12. HRCT Criteria for “Inconsistent With UIP Pattern”

13. Diagnosing IPF Based on HRCT and Histopathology Findings

14. Accurate Diagnosis of IPF Summary

15. Chronic Hypersensitivity Pneumonitis in Patients With Diagnosis of IPF

17. 2011 Evidence-based Guidelines for The Treatment of IPF

18. 2011 Evidence-based Guidelines

19. Prednisone, Azathioprine, and N-Acetylcysteine for IPF

20. Results of PANTHER-IPF Trial

21. Results of a Randomized, Placebo-controlled Trial of Warfarin in IPF

22. Would Anti-Reflux Therapy Benefit Patients With IPF?

23. Anti-Reflux Therapy for IPF

24. Recent Clinical Trials of Endothelin Receptor Antagonists in IPF

25. Pirfenidone (Investigational)

26. Nintedanib (Investigational)

27. Nintedanib (cont)

28. Results of 3 Completed Phase 3 Trials To Be Presented at 2014 ATS

29. Co-Trimoxazole

30. Additional Clinical Trials

31. Treatment of Comorbidities Also Important in IPF

32. Preventive Measures

33. How Standard of Care Has Improved

34. How Standard of Care Has Improved (cont)

35. Abbreviations

36. Abbreviations (cont)

37. References

38. References (cont)

39. References (cont)

40. References (cont)